Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 5/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.32 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.32 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.31 |
| ▸ | HNF4A | P41235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6086974 | 0.95 | PTPN1 (0.35) | THRATHRBRXRAPPARGNR1H3 | |
| SCHEMBL6086567 | 0.92 | RXRA (0.31) | RXRAPDE5A | |
| SCHEMBL6087079 | 0.87 | HTR2A (0.32) | RXRAHNF4A | |
| SCHEMBL6086934 | 0.84 | THRA (0.37) | THRATHRBRXRAS1PR3PPARG | |
| SCHEMBL6087995 | 0.84 | THRA (0.37) | THRATHRBRXRAS1PR3PPARG | |
| SCHEMBL6086294 | 0.81 | HTR2A (0.35) | — | |
| SCHEMBL6088216 | 0.79 | HTR2A (0.33) | — | |
| SCHEMBL6086506 | 0.77 | HTR7 (0.37) | THRATHRB | |
| SCHEMBL6087257 | 0.76 | SLC6A4 (0.31) | — | |
| SCHEMBL6087856 | 0.76 | GPR84 (0.35) | THRATHRBS1PR3S1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026487-B2 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, a pyridyl group and an alkyl group, having retinoid-like biological activity | ALLERGAN, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040097733-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | BEARD RICHARD L (US) | 2004-05-20 | — | — | US | disclosed |
| US-20030166932-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | ALLERGAN SALES, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6613917-B1 | Retinoid agonist, antagonist or negative hormone-like biological activity | ALLERGAN, INC. | 2003-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166932-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | NR4A1, NR2E3, NR0B1 | THRA 28/4885THRB 22/4885RXRA 13/4885 |
| US-20040097733-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | NR4A1, NR2E3, NR0B1 | THRA 28/4885THRB 22/4885RXRA 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.